Home | Welcome to Contract Pharma   
Last Updated Friday, December 19 2014


Topics - Biologics, Proteins, Vaccines

Refine by Date:
From: To:
Published December 15, 2014
Includes Czech production facility and assets for H5N1, H1N1 and seasonal flu vaccines Read More »
Published December 9, 2014
Merck gains expanded access to Azymetric platform Read More »
Published December 2, 2014
Continues expansion in the UK with £8 million investment Read More »
Published December 2, 2014
Catalent to provide cell line engineering, process development, and manufacturing Read More »
Published December 1, 2014
Attributes growth to rapidly developing biopharma industry and increase in CMOs globally Read More »
Published November 24, 2014
Aims to develop, manufacture, and distribute NewLink's rVSV-EBOV candidate Read More »
Published November 21, 2014
Increased production capacity to support maturing biologics pipeline Read More »
Published November 20, 2014
Incorporates multiple technologies aimed at greater speed and efficiency Read More »
Published November 14, 2014
The investment, upwards of $900 million, will support multiple therapies Read More »
Biosimilar Development: Where Are We Now?
By Fiona Greer , SGS Life Science Services
Published November 13, 2014
Recent developments indicate a growth surge. Read More »
Published November 7, 2014
Acquires Integra Companies and STI Components Read More »
Published October 31, 2014
To produce commercial quantities of a second biologic at Lonza’s Portsmouth facility Read More »
Published October 30, 2014
Will collaborate with Pontifax to invest in technologies to advance capabilities Read More »
Published October 28, 2014
Enhances capacity and capabilities for cell culture testing Read More »
Published October 28, 2014
Becomes second largest player in the $4 billion global flu vaccine industry Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On